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1199-70 seoclations of Plasma Vitamin D and Osteopotin Levels 
With Coronary Artery Calcif ication 
Yukihiko Momivama. Reiko Ohmod, Hircaki Taniguchi, Haruo Nakamure, Fumitaka 
Ohsuzu, Nationa/ Defense Medical Co/lege, Saitama, Japan. 
Background: Coronary calcification is a common finding in atherosclerotic plaques, and 
it was reported to be associated with adverse cardiac events. However, the mechanism 
of calcification remains unclear. Although ostaopontin (OPN) mRNA was reported to be 
highly expressed in calcified atherosclerotic plaques, any association of plasma OPN 
level with coronary calcification has not been elucidated. 
Methods: In addition to 25-hydroxyvitamin D3 (Vit D) level, plasma OPN level was mea- 
sured using a recently developed ELISA kit in 54 male patients (age 51 to 80 years) who 
underwent elective coronary angiography for suspected CAD. On coronary angiograms, 
the degree of calcification in each segment (CASS classification) was scored 0 to 3 
points. The extent of coronary plaques was evaluated as the numbers of >25% and 
>50% stanotic segments. Patients with diabetes, statin treatment or AMI were excluded. 
Results: Of the 54 patients, 36 (67%) had CAD (>50% stenosis), and 35 (65%) had cor- 
ocary calcification. The degree of coronary calcification (sum of scores) correlated welt 
with the numbers of >25% and >50% stanotic segments (r=0.74 and r=0.71, p<0.005). 
Calcification was associated with hypertension but not with serum lipid levels. As for 
plasma Vit D and OPN levels, the degree of calcification correlated negatively with Vit D 
level (r=-0.24, p<0,05) and positively with OPN level (r=0.32, <0.025). In contrast, the 
extent of coronary plaques was associated not only with hypertension but also negatively 
with HDL cholesterol evel. OPN level also correlated with the numbers of >25% and 
>50% stanotic segments (r=0.34 and r=0.28, p<0.0t), but Vit D level did not. Multivariate 
analysis revealed that plasma OPN level was significantly associated with the extent of 
plaques as well as the degree of calcification independent of risk factors and age. How- 
ever, Vit D level was associated only with the degree of calcification. 
Conclusions: Plasma OPN level was found to be associated with both the extent of cor- 
onary plaques and the degree of calcification, suggesting that OPN may be contributing 
to plaque formation and calcification in coronary arteries. However, Vit D was associated 
only with coronary calcification. 
1199-91 Quantitative Dose-Antlthrombotic Response of Direct 
Fector-Xa Inhibitor ZK-807834 in Stable Coronary 
Patients 
M. Urooi Zafar. Michael E. Farkouh, Julio Osende, Daichi Shimbo, Stalla Palencia, 
Valantin Fuster, James H. Chesebro, Mount Sinai School of Medicine, New York, New 
York, Mayo C/inic, Jacksonville, Florida. 
Backoround Tissue Factor pathway has s role in coronary artery disease [CAD] athero- 
thrombosis. Due to the Tissue Factor-Factor Vlta-Factor Xa interaction, blockade of Xa 
may decrease thrombus formation. Studies with Badimon Per'fusion Chamber [BC] have 
shown 40-55% thrombus reduction with abciximab but none with hepadn. We evaluated 
the close response of direct Xa inhibitor ZK-807834 [ZK], in stable CAD patients using the 
BC. 
Methods CAD patients (n=18, mean age=59 years, 56% males) were blindly random- 
ized to receive ZK (dosed to achieve PT ratios of 1.125, 1.5 and 2.5) or placebo as a 24 
hour [hi infusion. Formation of artedal thrombus was measured in the BC (shear 1690/ 
sec) st baseline (pretreatment), end of 24h infusion [Eol], and at 4h and 8h after EoL This 
design used each patient as his/her own control. 
Results For the low, med and high dose ZK groups, median % thrombus reductions from 
baseline to Eol were 34, 29 and 66% (p=0.03), and at 8h post Eol were 1.6, 7.3 and 38% 
respectively. Mean PT prolongations respectively were 1.2, 1.85 and 2.6 times baseline 
at Eol, and 1.1, 1.2 and 1.3 times baseline at 8h post Eol. The greatest hrombus reduc- 
tion at Eol (mean 62%+/- SE 11.1) and at 8h post Eol (30%+/-8.9) was observed with 
high dose ZK. 
Conclusion At moderate PT ratios, ZK reduces platelet-dch arterial thrombus growth 
similar to aboiximab or r-hirudin. ZK has a longer lasting antithrombotic effect at higher 
doses and due to its similar potency may reduce the need for additional potent acute 
antithrombotic agents. 
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1199-92 Acute Systemic Inf lammation Enhances Tissue 
Plasminogen Activator Release in Man 
Stanley Chia. Keith S. Reid, Pamela Dawson, Christopher A. Ludlam, Keith A. Fox, 
David E. Newby, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, 
United Kingdom. 
Background: Systemic inflammation and endogenous fibdnolysis play a major role in the 
pathogenesis of ischemic heart disease. Elevated plasma tissue plasminogen activator 
(t-PA) and inflammatory marker concentrations have been shown to be risk factors for 
future cardiovascular events. Using a mild systemic stimulus, we investigated the effects 
of inflammation on the acute release of t-PA in vivo in man. 
Methods: In a double-blind randomized placebo controlled crossover trial, Salmonella 
typhi vaccine or placebo was administered to seven healthy male volunteers on separate 
occasions at least two weeks apart. Six hours after the vaccination, forearm blood flow 
(FBF) was measured using bilateral venous occlusion plethysmography during intra-bra- 
chiaf infusions of the endothelium-dependent vasoditators bradykinin (40, 200, 1000 
pmol/min) and acetylcholine (5, 10, 20 mcg/min), and the endothelium-independent 
vasodilator sodium nitroprusside (2, 4, 8 mcg/min). Plasma samples, collected during 
intra-brachial bradykinin infusion, were assayed for t-PA antigen and activity. 
Results: Vaccination caused a rise in white ceil count (11.0 vs 7.7 xl0E9/L, p---O.003). In 
all studies, FBF increased following bradykinin, acetylcholine and sodium nitroprusside 
infusion (p<0.001, ANOVA) but there were no significant differences following vaccine or 
placebo administration. Following vaccination, there was a significant augmentation in 
the release of tPA antigen (p=0.016, 2-way ANOVA; 45+/-10 vs 22+/-9 ng/lO0 ml/min at 
peak dose) as well as active tPA (p=0.009, 2-way ANOVA; 109+/-16 vs 56+/-14 IU/100 
ml/min at peak dose) during bradykinin infusion. 
Conclusion: S. typhi vaccination generates a mild inflammatory reaction associated with 
a significant potentiation of bradykinin-induced t-PA release. We conclude that systemic 
inflammation enhances acute t-PA release in man. This suggests a pathogenetic link 
between inflammation, endogenous fibrinolysis and the future risk of cardiovascular 
events. The effects of prolonged systemic inflammation, including the potential to cause 
depletion of endothelial t-PA stores, now need to be explored. 
1199-93 ACE Inhibition and Tiseue Plasminogen Activator 
Release In Patients With Heart Failure 
Fraser N. Witherow. Christopher A. Ludlam, Keith A. Fox, David E. Newby, 
Cardiovascular Research, Edinburgh, United Kingdom, Dept of Haematology, Edinburgh, 
United Kingdom. 
Background: Bradykinin is an endogenous vasodilator peptide that is released during 
intravascular thrombosis and acute coronary syndromes, and is a potent stimulus for the 
release of tissue plasminogen activator (tPA). We have previously shown a modest (2 
fold) augmentation of bredykinin induced t-PA release in healthy volunteers maintained 
on ACE inhibitor therapy. The aim of the present study was to assess the effect of ACE 
inhibitor therapy on bredykinin induced tPA release in patients with chronic heart failure. 
Methods: Nine patients with NYHA grade II- IV heart failure, established for at least six 
months on ACE inhibitor therapy, attended on two occasions one week apart. ACE inhib- 
itor therapy was withheld for one week prior to the second visit. On each occasion, fore- 
arm blood flow (FBF) and plasma fibdnolytic parameters were measured using bilateral 
venous occlusion plethysmography, and bilatarel venous blood sampling. Following 30 
min equilibration with saline infusion, bradykinin at 30, 100 and 300 pmol/min, substance 
P at 2, 4 and 8 pmol/min and sodium nitroprusside at 1,2 and 4 pmol/min were infused 
into the brachial artery. 
Results: Bradykinin and substance P caused a dose-dependent vasodilatation and tPA 
release in the infused forearm on both days (ANOVA, p<0.001). In the presence of ACE 
inhibitor therapy, there was a 1.5-2 fold augmentation of bradykinin (2-way ANOVA, 
p<0.001), but not substance P or sodium nitroprusside, induced vasodilatation. ACE 
inhibitor therapy caused massive (6-10 fold) augmentation of bmdykinin induced tPA 
antigen and activity release (2-way ANOVA, p<0.001) without affecting substance P 
induced tPA release. 
Conclusions: Chronic ACE inhibitor therapy causes a massive and specific augmenta- 
tion of bredykinin induced tPA release. This may, in part, explain the anti-ischaemic 
effects of ACE inhibitor therapy in patients with heart failure 
1199-94 Relationship of Plasma von Willebrand Factor With 
Stroke Risk Factors in 1,321 Patients With Atrial 
Fibril lation 
Dwavne S. Conwav, Lesiy A. Pearce, Bernard S. Chin, Robert G. Hart, Gregory Lip, 
University Department of Medicine, City Hospital, Birmingham, United Kingdom, 
University of Texas at San Antonio, San Antonio, Texas. 
Background: Atrial fibrillation (AF) is a major cause of stroke, but the mechanisms are 
incompletely understood. Raised levels of plasma von Willebrend Factor (vWf, an index 
of endothelial dysfunction) have been described in AF, but the relation of vWf to stroke 
risk factors in AF is unclear. 
Methods: We measured plasma vWf levels (ELISA) in 1321 participants enrolled in the 
Stroke Prevention in AF (SPAF) III trial, and related vWf to risk factors for stroke in AF. 
Results: vWf levels increased with age (r = 0.18, p < 0.001), female sex (150 vs. 145iU/ 
dl, p=0.01), prior cerebral ischemia (154 vs. 145iU/dl, p<0.001), hypertension (149 vs. 
144iU/dl, p=0.001), recent heart failure (159 vs. 145iU/dl, p<0.001), diabetes (159 vs. 
145iU/dl, p<0.001), and fractional shortening ~ 25% (152 vs. 145iU/dl, p<0.01), but were 
not affected by systolic BP > 160 mmHg (149 vs. 146iU/dl, p = 0.3). Characteristics inde- 
pendently associated with vWf were: age (p<0.001), prior cerebral ischemia (p<0.01), 
recent CHF (p < 0.001 ) and diabetes (p<0.001). vWf increased with increasing stroke risk 
(SPAF III criteria, R2=8%, see below). Antithrombotic treatment effect was examined in 
high risk patients and did not differ between those randomised to adjusted dose warfarin 
vs. low dose warfarin + aspirin (151 vs. 149iU/dl, p=0.6). 
Plasma Levels of vWf According to SPAF Stroke Risk Stratification 
Overall Low Risk Moderate Risk High Risk P-value 
(n=1321) (n=376) (n=309) (n=636) 
Mean vWf iU/dl (SD) 147 (31) 140 (32) 145 (30) 152 (29) <0.001 
Conclusion: vWf levels were related to stroke risk factors in AF, with a graded increase 
between 'low', 'moderate' and 'high' risk patients. Stroke risk in AF appears to be related 
to endothelial damage/dysfunction. 
